Aprea Therapeutics (APRE) Net Equity Issued and Repurchased (2019 - 2026)

Aprea Therapeutics (APRE) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $35.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 59154.5% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $37.0 million (up 18382.95% YoY), while the FY2025 annual figure was $1.9 million, down 88.23% from the prior year.
• Net Equity Issued and Repurchased improved to $35.1 million in Q1 2026 per APRE's latest filing, from $1.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $35.1 million in Q1 2026 and bottomed at $59234.0 in Q1 2025.
• Historically, Net Equity Issued and Repurchased has averaged $6.6 million across 5 years, with a median of $400000.0 in 2025.
• Annual changes were most pronounced in 2025 — Net Equity Issued and Repurchased plunged 99.63% — and 2026, when it jumped 59154.5%.
• Aprea Therapeutics' Net Equity Issued and Repurchased stood at $98526.0 in 2022, then jumped by 5775.52% to $5.8 million in 2023, then tumbled by 97.57% to $140758.0 in 2024, then soared by 657.05% to $1.1 million in 2025, then surged by 3193.8% to $35.1 million in 2026.
• Business Quant data shows APRE's Net Equity Issued and Repurchased at $35.1 million in Q1 2026, $1.1 million in Q4 2025, and $400000.0 in Q3 2025.